Industry news that matters to you.  Learn more

MDxHealth Partners to Identify Predictive Biomarker for PARP Inhibition

Reading time: < 1 minute

MDxHealth has announced that they are partnering with Newcastle University in the UK, Cancer Research Technology and Pfizer to identify and develop biomarkers that can predict response to a PARP inhibitor.

The goal is to develop a companion diagnostic that could help physicians in the treatment of ovarian and breast cancer. PARP enzymes are involved in cellular DNA damage repair and a PARP inhibitor is currently under development by Newcastle University, Cancer Research Technology and Pfizer.

Under the terms of the agreement, MDxHealth will profile the methylation patterns of DNA damage repair genes to identify those that may predict response to PARP inhibition. They will also provide biomarker discovery services, assay development services and clinical trial testing.

Source: GenomeWeb